Company intelligence / Profile preview

Astellas Pharma

Ownership: Public · ALPMY
Development stage: Commercial

Overview

Astellas has a robust commercial portfolio with leading brands such as Xtandi® for prostate cancer and Padcev® for bladder cancer. Recent clinical milestones include FDA approvals of Vyloy™ for advanced gastric/GEJ cancers and expanded labels for Izervay™ in geographic atrophy. The company continues to advance novel modalities like targeted protein degraders into clinical development while expanding its cell/gene therapy pipeline through internal innovation and external partnerships

Therapeutic areas: OncologyInfectious DiseasesImmunologyOphthalmologyNephrologyWomen's Health
Modalities: Small moleculesbiologicsantibody-drug conjugates (ADCs)cell therapygene therapybioelectronics
Industry: Pharma

Drug pipeline

212 assets

conivaptan

Approved

211 more assets in the full pipeline.

Request access →

Financials

Market cap: $26.3B
Total revenue: $649.4B
Enterprise value: $369.2B

Beyond the preview

Go deeper on Astellas Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Astellas Pharma.

Explore the full profile